GlassScriptPhysician profile
Jeffrey P Andreini
NPI 1235266735
$4,710.84
in general payments reported to CMS, 2019-2025
25 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $346 · 2021: $778 · 2022: $647 · 2023: $852 · 2024: $1,089 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.89 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.79 | 2019-2025 | Viberzi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $647.25 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $525.28 | 2019-2024 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $436.40 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.11 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $295.44 | 2021-2024 | Zeposia |
| Pfizer INC. | $216.86 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $138.90 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $88.36 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $80.28 | 2019-2021 | |
| Qol Medical, LLC | $66.48 | 2023-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $65.95 | 2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $59.10 | 2019-2023 | Clenpiq |
| Daiichi Sankyo INC. | $53.82 | 2021-2022 | |
| Ardelyx, INC. | $49.03 | 2024 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $43.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.15 | 2020-2022 | |
| Lilly USA, LLC | $29.22 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $19.10 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.05 | 2024 | |
| Shionogi INC | $16.83 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.79 | 2020 | |
| Ethicon US, LLC | $16.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2023 | Cyltezo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Andreini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.